Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
By M. Dimopoulos, P. Moreau, A. Palumbo, D. Joshua, L. Pour, R. Hájek, T. Facon, H. Ludwig, A. Oriol, H. Goldschmidt and 21 more. The Lancet Oncology, 2016
787 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/799519e88d8d8cf3309035459d1151430c4198e3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “In another randomized trial, carfilzomib plus dexamethasone was associated with an improvement in PFS and OS compared with bortezomib plus dexamethasone in relapsed multiple myeloma.(150,151) However, the dose of carfilzomib used in this trial (56 mg/m(2)) is twice the standard dose, and carries a m”
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, result): “001 NR; 72% at 1 y Dimopoulos et al.(139,140) Vd 465 63 6 9 40 .”